Interested in the Genedrive share price? Read this first!

The Genedrive share price has produced large returns for investors this year, but can the company continue to outperform?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Genedrive (LSE: GDR) share price has been on a rollercoaster ride this year. The stock was trading at around 9p a share in March but then leapt to more than 200p in early May. 

The excitement started to build around the company due to its existing technology, which could identify pathogens relatively quickly. This technology, investors speculated, could help revolutionise the testing process for Covid-19. The organisation believed it could cut delays processing lab samples.

Unfortunately, the company’s progress has been slower than many investors may have projected. The practicalities of getting accurate products to market have hampered the business.

Consequently, these delays hurt investor sentiment towards the Genedrive share price. The stock has fallen as a result, currently changing hands at just over 111p, down around 50% from that May high. 

Steady progress 

Despite the slow progress, Genedrive is pushing forward. Following the CE marking of the Genedrive 96 SARS-CoV-2 kit at the end of May, management has been working to gain approval from regulators around the world to sell the product in different markets.

In the United States, Emergency Use Authorisation (EUA) has been applied for and remains under consideration by the FDA. Meanwhile, the approval process in Africa and India is well underway. The South African Health Products Regulatory Authority also approved the product at the end of September. 

The firm has also signed an agreement with Beckman Coulter Life Sciences to combine the Genedrive 96 SARS Cov 2 testing kit with the Biomek i7 automated work station. 

And on top of all of the above, Genedrive is working on a new Point-of-Care (POC) system for Covid-19. This product could produce results in approximately 15 minutes. 

Unlike many other early-stage healthcare companies, the business already has revenue commitments. Its latest trading update noted the firm had £1m of purchase commitments for the Genedrive 96 SARS-CoV-2 kit. Unfortunately, the company also noted it needs regulatory approval before these orders can be filled. 

Genedrive share price investment potential 

Still, from an investment perspective, I think the Genedrive share price looks attractive. One of the most common reasons why early-stage healthcare companies fail is lack of funds. That’s not something investors here need to be worried about right now.

At the end of June, Genedrive had £8.2m of cash on the balance sheet. I think that could be enough to sustain the business for at least two years. The company should have reached the revenue stage by that point. From there on, the sky could be the limit for Genedrive. 

As such, while the Genedrive share price has fallen in recent months, I think the firm’s fundamentals look much stronger today than they were at the beginning of the year. If the company’s testing products are approved around the world, the revenue opportunity could be substantial.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Should I sell my FTSE All-Share index fund and buy a S&P 500 tracker instead?

Harvey Jones is wondering whether now is a good time to invest more money in the S&P 500, after a…

Read more »

Investing Articles

Should I buy dirt-cheap BT shares after the recent pullback?

BT shares were on the up but now they're sliding again after the board trimmed full-year guidance. Now Harvey Jones…

Read more »

Investing Articles

Up 28%, can the easyJet share price keep rising?

The easyJet share price has gained altitude over one year but plunged over five. Is now an attractive time for…

Read more »

British Isles on nautical map
Investing Articles

Should I buy more BAE Systems shares at 1,350p?

BAE Systems shares have had a fantastic run since early 2022, yet still don't appear overvalued. Is it now time…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

7% yield and a cheap valuation! Is this one of the best shares to buy this month?

Christopher Ruane has been looking for cheap shares to buy. This one has a 7% dividend yield, so is it…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

Should I buy National Grid shares for the big dividend before it’s too late?

This year's price weakness has left National Grid shares on what looks like a tempting valuation. I hope it doesn't…

Read more »

Investing Articles

There are now 5,000 ISA millionaires! See the surprising UK dividend shares they’re buying

The number of ISA millionaires is growing all the time and guess what? They're really into blue-chip dividend shares listed…

Read more »

Blue NIO sports car in Oslo showroom
Investing Articles

Down 38% in weeks! Time to snap up NIO stock?

NIO stock's more than doubled in value over the past five years but has been on a wild ride lately.…

Read more »